About Traversa Therapeutics
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
Missing: Traversa Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Traversa Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Traversa Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Traversa Therapeutics is included in 3 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Latest Traversa Therapeutics News
Sep 20, 2013
See below. ] It was a quiet week for life sciences news in San Diego, except for a shooting spree in La Jolla that wounded two people, including a prominent UC San Diego cancer scientist. Here’s my rundown. —[Updated to show statement by Petersen about Traversa IP is in dispute] Hans Petersen, who was CEO of the defunct San Diego biotech Traversa Therapeutics, is being held without bail following his arrest yesterday in connection with a shooting spree that wounded two people in La Jolla. Police told U-T San Diego that Petersen, who was valedictorian of his 1998 University of San Diego MBA class, shot Steven Dowdy, a prominent UC San Diego cancer biologist and business partner at Traversa, and Ron Fletcher, a real estate investor and Petersen’s estranged brother-in-law. Traversa, which raised $10.5 million in venture equity and debt financing, filed for bankruptcy last year. Petersen wrote in his LinkedIn profile that some of Traversa’s proprietary technology in RNA interference was licensed to Dowdy’s company, Solstice Biologics. But that claim is disputed by investor Corey Goodman of VenBio, according to a BioWorld account. In an interview with the NBC affiliate in San Diego, Petersen’s ex-wife Bonnie Fletcher said she was terrorized by her ex-husband, who also blamed Dowdy for firing him and ruining the company. —OncoSec Medical, a San Diego company with electroporation technology for treating solid tumors, said it raised about $12 million through a public offering that included nearly 47.8 million shares of common stock at 25 cents a share and warrants to purchase another 23.9 million at 35 cents a share. OncoSec, which trades on the over-the-counter market under the ticker symbol ONCS, plans to use the proceeds for general corporate purposes, including clinical trial expenses and R&D. —The San Diego-based Gary and Mary West Foundation said it has provided an undisclosed grant to fund a new independent nonprofit organization, the Center for Medical Interoperability, to help hospitals make different types of medical technology work together. The center will be established with personnel and royalty-free technology licensed from the Gary and Mary West Health Institute. The Center will focus on developing and promulgating standards-based technical solutions to drive adoption of medical interoperability, so that health information to be seamlessly shared among medical devices and enterprise health systems to optimize health care delivery. The center’s executive director is Ed Cantwell, previously lead of the medical grade wireless utility at the West Health Institute. —In a new strategic initiative, San Diego’s Aethlon Medical said it is launching a new business based on a “dormant and unvalued diagnostic” to diagnose and monitor the progression of cancer, infectious disease, and other life-threatening conditions. The company’s subsidiary, Exosome Sciences, has technology to detect exosomes produced by diseased cells. CEO Jim Joyce said Aethlon’s primary focus would remain commercializing its hemopurifier technology. Aethlon trades on the over-the-counter market under the ticker symbol AEMD. —San Diego’s Prometheus Laboratories named Lisa Miller as CEO. She was previously a corporate vice president at DAKO, an Agilent Technologies company based in Copenhagen, Denmark, where she was responsible for their global cancer diagnostics business. Miller has more than 25 years of experience in medical diagnostics and devices.
Traversa Therapeutics Frequently Asked Questions (FAQ)
When was Traversa Therapeutics founded?
Traversa Therapeutics was founded in 2006.
Where is Traversa Therapeutics's headquarters?
Traversa Therapeutics's headquarters is located at 505 Coast Boulevard South, La Jolla.
What is Traversa Therapeutics's latest funding round?
Traversa Therapeutics's latest funding round is Series B.
How much did Traversa Therapeutics raise?
Traversa Therapeutics raised a total of $7M.
Who are the investors of Traversa Therapeutics?
Investors of Traversa Therapeutics include Mesa Verde Venture Partners, Morningside Ventures and San Diego Tech Coast Angels.
Who are Traversa Therapeutics's competitors?
Competitors of Traversa Therapeutics include Lead Pharma, Regulus Therapeutics, Curetis, Oxford BioTherapeutics, Intarcia Therapeutics, Profectus BioSciences, Intercept Pharmaceuticals, Icagen, Forte Biosciences, Anacor Pharmaceuticals and 33 more.
Compare Traversa Therapeutics to Competitors
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Chimeros is developing a biologics approach to enable delivery of polynucleotide therapeutics such as siRNAs. The company's delivery technology, termed Chimerasomes, is based upon protein building blocks that can bind these therapeutic payloads and subsequently be triggered to self-assemble into nanocages, thereby encapsulating the polynucleic acids. The surface of the nanocages can subsequently be decorated with targeting moieties such as antibodies or with PK/ biodistribution modulating molecules such as PEG polymers and lipid coatings.
JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).
Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.
OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.